Wire · opportunities
FDA approves Roche's Enspryng, a first-in-class IL-6R inhibitor, as the first and only at ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 October 2026 · Fusion42 review
The FDA has approved Roche's Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED), based on Phase III SatraGO-1 and -2 clinical trials demonstrating significant efficacy and a favourable safety profile.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You can now offer patients with thyroid eye disease a convenient at-home treatment option that reduces reliance on clinical infusion centres. This approval opens up potential to expand treatment accessibility and reduce costs linked to infusion-based therapies.
◆ Coverage
2 sources · 16 Oct 2026
◆ Related on Wire
◆ Topics